Get notified when XERS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: XERS Xeris Biopharma Holdings, Inc. 8-K

Xeris retires all $33.5M of 2028 convertible notes via debt-for-equity exchanges

Filed July 17, 2026 · Period ending July 15, 2026 · ~1 min read

Key Changes

  • high

    Completed exchange of ~$23M principal for 5.0M shares plus $23M cash and separate conversion of $10.5M principal into 3.6M shares, eliminating entire 2028 convertible note obligation

  • high

    Funded $23M cash portion with existing liquidity; issued total ~8.6M shares to noteholders

  • medium

    Shares issued unregistered under Section 4(a)(2) exemption to institutional accredited investors (exchange) and Section 3(a)(9) exemption (conversion)

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.

Partner

Trade XERS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jul 19, 2026 · How we verify